My new paper showing that a new proteasome inhibitor Marizomib suppresses triple-negative breast cancer primary growth, and lung and brain metastases. https://t.co/Hm1IO61qRO #Theranostics
Thank you @CureCancerAu for funding this work.
Extremely glad to receive the Fund for New Research grant from ANZGOG for my ovarian cancer research. Thank you @anzgog and @QIMRBerghofer for a continued support.
Presenting my work today on synergistic anti-cancer activity of auranofin and anti-PD-L1 combination therapy in #TNBC at the European Socirty for Medical Oncology Congress in Spain. Glad to receive positive feedback from fellow researchers! Thank you @EACRnews for travel award.
Our recent paper on using #goldcompounds to treat multiple myeloma. Thank you @CureCancerAu, @QIMRBerghofer and @Griffith_Uni supporting my research. https://t.co/LR9lkVt6bi
Our recent paper on using #goldcompounds to treat multiple myeloma. Thank you @CureCancerAu, @QIMRBerghofer and @Griffith_Uni supporting my research. https://t.co/LR9lkVt6bi
We have recently published our findings on the anti-cancer activity of an FDA-approved drug in combination with anti-PD-L1 therapy for triple-negative breast cancer. We thank @CancerAustralia and @CureCancerAu for funding this work and @QIMRBerghofer. https://t.co/Uf6JgJ4J9E
Triple-negative #breastcancer is very aggressive & lethal with poor prognosis. Only 25% TNBC patients respond to conventional #chemotherapy. Prahlad Raninga @QIMRBerghofer shows he is using a novel proteasome inhibitor to treat primary & #metastatic triple-negative breast cancer